California Lawmakers Reject Bill To Remove Marijuana Employment Protections For Some Law Enforcement Jobs
State AGs And Former DEA Leaders Push Agency To Hold Public Hearing On Marijuana Rescheduling Proposal
North Carolina Senate Gives Initial Approval To Bill That Would Legalize Medical Marijuana In Rebuke Of House Opposition
Biden ‘Commends And Welcomes’ Maryland Governor’s Mass Marijuana Pardon, White House Says
Pennsylvania Could See Up To $2.8 Billion In Marijuana Sales In First Year Of Legalization And Create 45,000 Jobs, Analysis Finds
Older Patients Using Medical Cannabis ‘Experience Considerable Improvement In Health And Well-Being,’ Study Finds
Youth See Reddit As ‘Viable Outlet’ For Marijuana Info, But Posts Often Have ‘Lack Of Verifiable’ Facts, Study Finds
People’s Use Of Alcohol Or Opioids Causes Greater Secondhand Harms Than Marijuana Consumption Does, Study Finds
Youth Marijuana Use In Colorado Continues To Decline Since Legalization Took Effect, Contradicting Prohibitionist Fears
Communities Closer To Marijuana Dispensaries Have Lower Opioid Prescription Rates, New Study Finds
California State Fair Will Allow Marijuana Sales And On-Site Consumption For First Time
Marijuana Rolling Paper Company Will Pay $4.20 To Volunteers To ‘Smoke Joints For Science’
NFL Sued By Player Who Was Fined Over $500,000 For Positive THC Tests Caused By Prescribed Cannabis Medication
Brands And Advocacy Groups—From ACLU To KFC—Launch 4/20 Promotions To Mark The Marijuana Holiday
Former Minnesota Gov. Jesse Ventura Promotes New Cannabis Brand Ahead Of 4/20 That He’d ‘Offer To You’ On Governor’s Mansion Visit
Oregon’s First-In-Nation Psilocybin Industry Is Struggling To Find Paying Customers A Year After Launching
States Have Generated Over $20 Billion In Marijuana Tax Revenue Since First Markets Opened, New Report Finds
Arkansas Medical Marijuana Dispensary Gets License Revoked Over Alleged Violations
New Jersey Set A New Marijuana Sales Record Last Quarter, With Regulators Touting ‘Historical Highs’ On 4/20 Weekend
Massachusetts Saw Record-Breaking Marijuana Sales On 4/20, Pushing State Across $6 Billion Mark For Recreational Purchases
Biden ‘Commends And Welcomes’ Maryland Governor’s Mass Marijuana Pardon, White House Says
Maryland Governor Pledges To Work With Lawmakers On Marijuana Expungements To Build On His Mass Pardon Move
New York Governor Links Illicit Marijuana Shop Crackdown To ‘Dramatically’ Increased Legal Sales, As Equity-Focused Activists Protest Administration
Marijuana Rescheduling Opponents Slam FDA Process, Saying It Relied On ‘Very Bad Studies’
Maryland Governor Pardons More Than 175,000 Marijuana And Paraphernalia Convictions
Pennsylvania cannabis legalization has enough votes to pass, senators say (Newsletter: June 20, 2024)
Calif. State Fair to allow cannabis use & sales on site (Newsletter: June 19, 2024)
Maryland governor issues mass cannabis pardons (Newsletter: June 18, 2024)
Cannabis testing ban for military recruits passes House (Newsletter: June 17, 2024)
Cannabis banking setback in Congress (Newsletter: June 14, 2024)
Published
on
By
Single-dose psilocybin use is “not associated with risk of paranoia,” while other adverse effects such as headaches are generally “tolerable and resolved within 48 hours”—according to a new scientific review published by the American Medical Association (AMA).
With increased public interest in the therapeutic potential of psychedelics, researchers at the University of Georgia, Larkin University and Palm Beach Atlantic University set out to better understand possible negative effects of receiving psilocybin treatment.
The study, published in JAMA Psychiatry on Wednesday, involved a meta-analysis of double-blind clinical trials where psilocybin was used to treat anxiety and depression from 1966 to last year.
While psychedelics are sometimes portrayed in media as causing intense paranoia, particularly in a recreational setting, the study authors said psilocybin “was not associated with risk of paranoia and transient thought disorder.”
The researchers identified five other reported adverse effects among certain patients in the clinical trials: headache, nausea, anxiety, dizziness and elevated blood pressure. But they said the acute adverse effect profile of therapeutic single-dose psilocybin appeared to be “tolerable and resolved within 48 hours.”
“However, future studies need to more actively evaluate the appropriate management of adverse effects,” the study says.
While serious adverse effects like paranoia and prolonged visual perceptual effects were “infrequent,” the team stressed that those rare cases “warrant attention” and should be “monitored over the long term.”
“The effectiveness of medications and alternative treatments in managing these symptoms requires further investigation,” the study says. “Additionally, the role of licensed therapists in managing adverse effects presents an avenue for future research.”
Meanwhile, AMA published a separate study last month that similarly contradicted commonly held beliefs about the potential risks of psychedelics use, finding the substances “may be associated with lower rates of psychotic symptoms among adolescents.”
Also, result of a clinical trial published by AMA in December “suggest efficacy and safety” of psilocybin-assisted psychotherapy for treatment of bipolar II disorder, a mental health condition often associated with debilitating and difficult-to-treat depressive episodes.
The association also published research last August that found people with major depression experienced “clinically significant sustained reduction” in their symptoms after just one dose of psilocybin.
Another recent study suggests that the use of full-spectrum psychedelic mushroom extract has a more powerful effect than chemically synthesized psilocybin alone, which could have implications for psychedelic-assisted therapy. The findings imply that the experience of entheogenic mushrooms may involve a so-called “entourage effect” similar to what’s observed with cannabis and its many components.
More Than 90% Of Smokable Hemp Samples Analyzed By Researchers Contained Illegal Amounts Of THC, New Federal Study Finds
Photo courtesy of Dick Culbert.
Medical Marijuana Patient Enrollment Grew 610% Since 2016, Showing ‘Increasing Cultural Acceptance Of Cannabis,’ Federal Study Finds
More Than 90% Of Smokable Hemp Samples Analyzed By Researchers Contained Illegal Amounts Of THC, New Federal Study Finds
Kyle Jaeger is Marijuana Moment’s Sacramento-based managing editor. His work has also appeared in High Times, VICE and attn.
All the cannabis news you need, all in one place. Copyright © 2017-2024 Marijuana Moment LLC ® and Tom Angell
Use Of Psilocybin For Mental Health Treatment 'Not Associated' With Risk Of Paranoia, American Medical Association Study Finds – Marijuana Moment
